House committee approves bill on speeding medical innovation

first_img Country * Afghanistan Aland Islands Albania Algeria Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia, Plurinational State of Bonaire, Sint Eustatius and Saba Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory Brunei Darussalam Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Congo, the Democratic Republic of the Cook Islands Costa Rica Cote d’Ivoire Croatia Cuba Curaçao Cyprus Czech Republic Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands (Malvinas) Faroe Islands Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Gambia Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and McDonald Islands Holy See (Vatican City State) Honduras Hungary Iceland India Indonesia Iran, Islamic Republic of Iraq Ireland Isle of Man Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Korea, Democratic People’s Republic of Korea, Republic of Kuwait Kyrgyzstan Lao People’s Democratic Republic Latvia Lebanon Lesotho Liberia Libyan Arab Jamahiriya Liechtenstein Lithuania Luxembourg Macao Macedonia, the former Yugoslav Republic of Madagascar Malawi Malaysia Maldives Mali Malta Martinique Mauritania Mauritius Mayotte Mexico Moldova, Republic of Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island Norway Oman Pakistan Palestine Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Qatar Reunion Romania Russian Federation Rwanda Saint Barthélemy Saint Helena, Ascension and Tristan da Cunha Saint Kitts and Nevis Saint Lucia Saint Martin (French part) Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Sint Maarten (Dutch part) Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Islands South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syrian Arab Republic Taiwan Tajikistan Tanzania, United Republic of Thailand Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu Uganda Ukraine United Arab Emirates United Kingdom United States Uruguay Uzbekistan Vanuatu Venezuela, Bolivarian Republic of Vietnam Virgin Islands, British Wallis and Futuna Western Sahara Yemen Zambia Zimbabwe Email Sign up for our daily newsletter Get more great content like this delivered right to you! Country Click to view the privacy policy. Required fields are indicated by an asterisk (*)center_img A major congressional effort to spur medical innovation passed another milestone today when a House of Representatives committee signed off on the 21st Century Cures Act.The bill, developed by representatives Fred Upton (R–MI) and Diana DeGette (D–CO), revamps policies and provides new funding for the National Institutes of Health (NIH) and the Food and Drug Administration (FDA). Approved unanimously by the House Energy and Commerce Committee, the bill contains a few changes from a version introduced in April.As before, the measure authorizes annual $1.5 billion raises to NIH’s budget for 3 years and also provides $10 billion over 5 years in mandatory funding for a new NIH Innovation Fund. Annually, at least $500 million of the fund will support the new Accelerating Advancement Program, which would provide matching funds for NIH’s 27 institutes and centers for research in areas including biomarkers, precision medicine, infectious diseases, antibiotics, and basic research. The remainder would go to young scientists (at least 35%); high-risk, high-reward research; and NIH intramural research. This is somewhat different from an April draft bill that would have directed the Innovation Fund to young scientists, precision medicine, and a third, unnamed category. The current bill has also revised requirements for a new NIH 5-year strategic plan. An early draft called for NIH to make “resource allocation decisions” in line with economic considerations. Now, the plan is to be shaped mainly by “scientific opportunities,” wording changes supported by the biomedical research community. The bill also creates a controversial “capstone award” for senior scientists to wind down or pass on their research programs.As part of reforms to FDA, the latest draft tries to address concerns that the many new requirements of the agency under the bill would stretch its limited resources. These include gathering data on the natural history of diseases, incorporating patient feedback into the evaluation of new therapies, and qualifying new drug development tools like biomarkers that measure a patient’s response to a drug. A new amendment would set up a Cures Innovation Fund to dole out an annual $110 million for the next 5 years for several of these projects.The lawmakers have also reinserted a provision giving 6 additional months of marketing exclusivity to drugs approved for rare diseases, an incentive for drugmakers that had been removed in a previous version.The bill goes next to the House floor for a vote; Upton and DeGette are aiming to pass it this year. It will then need to be reconciled with the Senate’s version. Lawmakers in the Senate’s Health, Education, Labor and Pensions Committee are slowly developing their own biomedical innovation bill, but they haven’t indicated a timeline for its introduction.With reporting by Kelly Servick.last_img

Leave a Reply

Your email address will not be published. Required fields are marked *